Via Merck KGaA deal, GSK adds to growing immuno-oncology pipeline
By Mark Zipkin | Feb 5, 2019 | 11:39 PM GMT
Two months after announcing it would pay $5.1 billion for Tesaro Inc., GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) has partnered with Merck KGaA (Xetra:MRK) in another deal to bolster its immuno-oncology pipeline.
GSK is paying the German
Read the full 340 word article
User Sign In
This article may not be distributed to non-subscribers
PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD